• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Cala Health launches trial for Cala Two neurostim device for essential tremor

Cala Health launches trial for Cala Two neurostim device for essential tremor

January 17, 2019 By Brad Perriello

Cala HealthCala Health last month launched a clinical trial of the latest version of its wearable neurostimulator for treating essential tremor, eyeing extended use of the wrist-worn device.

The Burlingame, Calif.-based company won de novo clearance from the FDA last April for the Cala One device for transient relief in adults with essential tremor. The 500-patient, single-arm Prospect trial is designed to evaluate the Cala Two device for symptomatic relief for three months, with patients undergoing two daily treatments of 40 minutes each, separated by at least two hours.

Prospect’s primary outcomes include the subset score using the Tremor Research Group’s Essential Tremor Rating Assessment Scale, which rates six tasks from zero to four, with a higher score indicating more severe tremor; and the subset score using the Bain & Findley Activities of Daily Living, which rates eight tasks on the same 0-4 scale, according to ClinicalTrials.gov. Secondary outcomes include changes in kinematic measurements collected by Cala Two during postural holds. The study’s primary completion date is set for June, with an estimated completion date in September.

The first patients were enrolled in December 2018 at the University of South Florida Morsani College of Medicine in Tampa and USC’s Keck School of Medicine in Los Angeles, Cala Health said.

“People with essential tremor have their daily routine constantly disrupted and are looking for ways to control it,” Keck’s Dr. Mark Lew said in prepared remarks. “Our study aims to explore electrical stimulation via wearable therapy in the hopes of providing relief for those experiencing essential tremor.”

“The Prospect study will expand our understanding of patient benefit of CALA TWO by studying its therapeutic effect over a three-month period,” added Dr. Theresa Zesiewicz of the University of South Florida. “This therapy holds the promise to increase accessibility of an effective, non-invasive treatment option for hand tremors.”

Filed Under: Clinical Trials, Neuromodulation/Neurostimulation Tagged With: Cala Health

More recent news

  • Real-world data backs Route 92 reperfusion system
  • LivsMed unveils new surgical robot with telesurgery capabilities
  • JenaValve enrolls first patient in TAVR for AR study
  • HistoSonics expands insurance coverage for histotripsy treatment
  • Johnson & Johnson MedTech gets updated FDA nod for Varipulse PFA

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy